RxDoctor Payments Data

Kathleen McCarvell, APRN

Nurse Practitioner · Ansonia, CTNPI 1154500981

Payments from drug & device makers

$2,306in general payments, 2019–2025

Across 29 payments — averaging $79.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$533
  • Johnson & Johnson$481
  • E.r. Squibb & Sons, L.L.C.$309
  • Neurocrine Biosciences, Inc.$308
  • AbbVie$174
  • Otsuka America Pharmaceutical, Inc.$143
  • plus $359 from 3 others

What the payments were for

  • Food & beverage$2,22596%
  • Education$824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,306 in reported general payments places this provider in the 90th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$16,815
Medicare patients
53
Services billed
196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$142,232
Invega TrinzaPaliperidone Palmitate12$111,506
Invega SustennaPaliperidone Palmitate19$69,089
CaplytaLumateperone Tosylate40$63,816
LybalviOlanzapine/Samidorphan Malate11$17,698
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl50$15,789
Lurasidone Hcl79$11,409
Clozapine OdtClozapine20$10,162
Olanzapine144$8,497
Clozapine84$5,199
BelsomraSuvorexant11$4,920
Paliperidone ErPaliperidone15$3,579
Quetiapine Fumarate178$3,373
Quetiapine Fumarate ErQuetiapine Fumarate42$3,269
Duloxetine Hcl87$3,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$481$180,59631 claims
Neurocrine Biosciences, Inc.Ingrezza$308$142,23218 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$533$63,81640 claims
Alkermes, Inc.Lybalvi$127$17,69811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Ansonia

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →